Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 11/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | IDE | P14735 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27218036 | 0.87 | RET (0.47) | MC4RRET | |
| SCHEMBL19481747 | 0.85 | PARP1 (0.40) | ALDH1A1RETIDEMAPK1LMNA | |
| SCHEMBL19481772 | 0.85 | PARP1 (0.40) | ALDH1A1RETIDEMAPK1LMNA | |
| SCHEMBL19481750 | 0.85 | PARP1 (0.40) | ALDH1A1RETIDEMAPK1LMNA | |
| SCHEMBL19481825 | 0.85 | MC4R (0.41) | MC4RALDH1A1 | |
| SCHEMBL19481805 | 0.85 | PARP1 (0.41) | ALDH1A1RETIDEMAPK1LMNA | |
| SCHEMBL19459170 | 0.84 | MC4R (0.40) | MC4RALDH1A1RETIDEMAPK1 | |
| SCHEMBL19482040 | 0.84 | KIT (0.37) | MC4RALDH1A1RETKDM4ESMN1; SMN2 | |
| SCHEMBL19482039 | 0.84 | KIT (0.37) | MC4RALDH1A1RETKDM4ESMN1; SMN2 | |
| SCHEMBL19482038 | 0.84 | KIT (0.37) | MC4RALDH1A1RETKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2026-04-07 | — | — | US | disclosed |
| US-20240158398-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2024-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158398-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | MC4R 3673/4885ALDH1A1 3277/4885RET 50/4885 |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVRL1, ACVR2A | MC4R 2617/4885ALDH1A1 2050/4885RET 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.